

Certificate of Analysis

EphA7, active

(Recombinant enzyme expressed in Sf21 insect cells)

Item # 14-672

Lot # 1638877

From bulk lot # D8KN008U

Product Description: N-terminal 6His-tagged, recombinant human EphA7, amino acids 613–909, expressed by baculovirus in Sf21 insect cells. Purified using Ni²⁺/NTA agarose. Purity 98% by SDS-PAGE and Coomassie blue staining. MW = 38kDa.

Specific Activity (lot# 1638877): 53U/mg, where one unit of EphA7, active activity is defined as 1nmol phosphate incorporated into 100μM PDKtide per minute at 30°C with a final ATP concentration of 100μM.

Formulation: 2.774mg/ml of enzyme in 50mM Tris/HCl pH7.5, 300mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1% 2-mercaptoethanol. Frozen solution.

Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.



**FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS**

Quality Control Testing

Kinase Assay: 22.01–60.64ng of this lot of enzyme phosphorylated 100μM PDKtide in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.

MS Tryptic Fingerprint: Confirmed identity as EphA7 with the translated native sequence listed on page three.

SDS-PAGE and Coomassie Stain: Purity was assessed by SDS-PAGE and Coomassie blue staining using 3μg of EphA7, active.



Certificate of Analysis

Kinase Assay Protocol

Stock Solutions:

- 1. 5 x Reaction Buffer:** 40mM MOPS-NaOH pH7.0, 1mM EDTA.
- 2. PDKtide (KTFCGTPEYLAPEVRREPRILSEEE QEMFRDFDYIADWC):** Use at a final assay concentration of 100 μ M. Prepare a 1mM stock. Add 2.5 μ l of stock per assay point.
- 3. EphA7, active:** Dilute with 20mM MOPS-NaOH pH 7.0, 1mM EDTA, 0.01% Brij-35, 5% glycerol, 0.1% 2-mercaptoethanol, 1mg/ml BSA. Use 22.01–60.64ng per assay point.
- 4. [γ -³³P]ATP:** 2.5 x magnesium acetate/[γ -³³P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [γ -³³P]ATP (specific activity approximately 500 - 800cpm/pmol as required.)

Assay Procedure (96 well plate format):

1. Add 5 μ l of 5 x reaction buffer per assay to wells.
2. Add 2.5 μ l of **PDKtide (KTFCGTPEYLAPEVRREPRILSEEEQEMFRDFDYIADWC)**.
3. Add **2.5 μ l (22.01–60.64ng) EphA7, active**.
4. Add 5 μ l of dH₂O.
5. Add 10 μ l of diluted [γ -³³P]ATP mixture.
6. Incubate for 10 minutes at 30°C.
7. Stop the reaction by adding 5 μ l of 3% phosphoric acid.
8. Transfer a 10 μ l aliquot onto the appropriate area of a **P30 Filtermat**.
9. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
10. Wash the filtermat once for 2 minutes with methanol.
11. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
12. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1 μ l of 30% phosphoric acid.

Certificate of Analysis

EphA7 Sequence Information

<u>Protein</u>	human EphA7
<u>Tags</u>	N-Terminal 6His
<u>Native sequence</u>	T37of the recombinant sequence is equivalent to T613 of native human EphA7
<u>Accession number</u>	GenBank NM_004440

Recombinant EphA7 amino acid sequence:

```

1 MSYYHHHHHH DYDIPTTENL YFQGAMDPEF KGLRRQTYED PNRAVHQFAK ELDASCIKIE
61 RVIGAGEFGE VCSGRLKLPK KRDVAVAIKT LKVGYTEKQR RDFLCEASIM GQFDHPNVVH
121 LEGVVTRGKP VMIVIEFMEN GALDAFLRKH DGQFTVIQLV GMLRGIAAGM RYLADMGYVH
181 RDLAARNILV NSNLVCKVSD FGLSRVIEDD PEAVYTTTGG KIPVRWTAPE AIQYRKFTSA
241 SDVWSYGIVM WEVMSYGERP YWDMNQDVI KAIEEGYRLP APMDCPAGLH QLMLDCWQKE
301 RAERPKEFEQI VGILDKMIRN PNSLKTPLGT CSR

```

Recombinant EphA7 nucleotide sequence:

```

1 atgtcgtact accatcacca tcaccatcac gattacgata tcccaacgac cgaaaacctg
61 tatttttcagg gcgccatgga tccggaattc aaaggcctac gtcgacagac ctatgaggac
121 ccaaataagag ctgtccatca attcgccaag gagctagatg cctcctgtat taaaattgag
181 cgtgtgattg gtgcaggaga attcgggtgaa gtctgcagtg gccgtttgaa acttccaggg
241 aaaagagatg ttgcagtagc cataaaaacc ctgaaagttg gttacacaga aaaacaaagg
301 agagactttt tgtgtgaagc aagcatcatg gggcagtttg accacccaaa tgttgtccat
361 ttggaagggg ttgttacaag agggaaacca gtcattgatg taatagagtt catggaaaat
421 ggagccctag atgcatttct caggaaacat gatgggcaat ttacagtcac tcagtttagta
481 ggaatgctga gaggaattgc tgctggaatg agatatttgg ctgatatggg atatgttcac
541 agggaccttg cagctcgcaa tattcttgctc aacagcaatc tcgtttgtaa agtgtcagat
601 tttggcctgt cccgagttat agaggatgat ccagaagctg tctatacaac tactggtgga
661 aaaattccag taaggtggac agcaccgcaa gccatccagt accggaaatt cacatcagcc
721 agtgatgtat ggagctatgg aatagtcatg tgggaagtta tgtcttatgg agaaagacct
781 tattgggaca tgtcaaatca agatgttata aaagcaatag aagaaggtta tcgtttacca
841 gcacccatgg actgcccgagc tggccttcac cagctaattg tggattgttg gcaaaaggag
901 cgtgctgaaa ggccaaaatt tgaacagata gttggaattc tagacaaaat gattcgaaac
961 ccaaatagtc tgaaaactcc cctgggaact tgtagtaggt aa

```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services.